ArticleEULAR rheumatology open2026

Phase I trial in participants with rheumatoid arthritis and healthy volunteers with CIT-013, a first-in-class extracellular traps targeted therapy.

Micha N Ronner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.